Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma
Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma. Laura Finn, MD, associate program director, Hematology/Oncology Fellowship Program, associate program director, Bone Marrow Transplant, hematology research chair, Precision Cancer Therapies Program, Ochsner Health, discusses the utility of belantamab mafodotin-blmf (Blenrep) in late relapsed multiple...
www.onclive.com
Comments / 0